The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwAL 2025 | Clonal hematopoiesis screening in patients receiving cytotoxic chemotherapy
Koichi Takahashi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the standardization of clonal hematopoiesis screening for patients receiving cytotoxic chemotherapy, to identify those at high risk of developing therapy-related acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Dr Takahashi suggests that screening should be considered for high-risk populations, but is opposed to widespread screening for all cancer patients. This interview took place at the 7th International Workshop on Acute Leukemias (iwAL 2025), held in Washington, DC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think this has been debated a lot in the field and I think clonal hematopoiesis screening should be standardized for really high-risk populations. For example, multiple myeloma patients who undergo autologous stem cell transplant, this is a population where we see the highest risk of therapy-related MDS/AML development. So I think screening clonal hematopoiesis in that population is definitely reasonable to do...
I think this has been debated a lot in the field and I think clonal hematopoiesis screening should be standardized for really high-risk populations. For example, multiple myeloma patients who undergo autologous stem cell transplant, this is a population where we see the highest risk of therapy-related MDS/AML development. So I think screening clonal hematopoiesis in that population is definitely reasonable to do. But I’m probably opposed to just screening clonal hematopoiesis for all cancer patients, including solid tumor patients, who generally have a low-risk potential to develop therapy-related MDS/AML development.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
